- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Camurus AB (CAMX)
Assess today's live Camurus AB (CAMX) share price, performance and insights using our live Stockholm: CAMX stock exchange data.
Analyse the historical data and Camurus AB share price performance charts on this page. Our technical summary section provides analysis on Camurus AB share price buy/sell indicators using real-time data (or discuss the Camurus AB (CAMX) stock price today with other investors in the Camurus AB ST share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current ST CAMX share price (ISIN: SE0007692850) to enhance your trading decisions with our free investment tools and resources.
What Is the Camurus AB Share Price Today?
The Camurus AB share price today is 688.50.
What Is the Stock Symbol for Camurus AB
The stock symbol (or 'ticker') for Camurus AB is "CAMX."
What Stock Exchange Does Camurus AB Trade On?
Camurus AB is listed and trades on the Stockholm stock exchange.
Is Camurus AB a Good Stock to Buy?
Determining whether Camurus AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Camurus AB share price performance charts on this page. Our technical summary section provides analysis on Camurus AB share price buy/sell indicators using real-time data (or discuss the Camurus AB (CAMX) stock price today with other investors in the Camurus AB ST share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current ST CAMX share price (ISIN: SE0007692850) to enhance your trading decisions with our free investment tools and resources.
What Is the Camurus AB Share Price Today?
The Camurus AB share price today is 688.50.
What Is the Stock Symbol for Camurus AB
The stock symbol (or 'ticker') for Camurus AB is "CAMX."
What Stock Exchange Does Camurus AB Trade On?
Camurus AB is listed and trades on the Stockholm stock exchange.
Is Camurus AB a Good Stock to Buy?
Determining whether Camurus AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
688.50
-1.00(-0.15%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
685.00
696.00
52 wk Range
483.80
754.50
CAMX is included in our AI-picked strategies. See how they work
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
685.00696.00
52 wk Range
483.80754.50
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CAMX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
808.83
Upside
+17.48%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy
Camurus AB Company Profile
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; and Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; as well as NewBridge Pharmaceuticals. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Camurus AB Earnings Call Summary for Q3/2025
- Camurus Q3 2025 revenue grew 18% to 575M SEK with 43% profit margin, but stock fell 6.97% as results missed forecasts and full-year revenue guidance was lowered to 2.3-2.6B SEK
- Product sales increased 8% YoY to 455M SEK, driven by Buvidal/Brixadi which achieved 30% market share in US long-acting buprenorphine market despite challenges in UK and Germany
- Profit before tax rose 48% YoY to 245M SEK with strong cash position of 3.5B SEK (28% increase YoY), allowing company to maintain profit guidance of 0.9-1.2B SEK
- CEO Fredrik Tiberg reaffirmed 2027 vision of reaching 100,000 patients while preparing for OxyESA launch in European markets at pricing just under €3,000 per dose
- Key risks include funding challenges in European markets, potential US market saturation, possible delays in product trials, and currency fluctuation impacts on international operations
Last Updated: 06/11/2025, 14:00
Read Full TranscriptCompare CAMX to Peers and Sector
Metrics to compare | CAMX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCAMXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 52.6x | 16.4x | −0.6x | |
PEG Ratio | 0.28 | 6.72 | 0.00 | |
Price/Book | 10.0x | 3.2x | 2.6x | |
Price / LTM Sales | 17.5x | 3.8x | 3.4x | |
Upside (Analyst Target) | 16.8% | 74.2% | 42.0% | |
Fair Value Upside | Unlock | 10.2% | 5.0% | Unlock |
Analyst Ratings
6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 808.83
(+17.48% Upside)
Earnings
Latest Release
Nov 06, 2025
EPS / Forecast
3.27 / 3.53
Revenue / Forecast
567.00M / 625.65M
People Also Watch
FAQ
What Is the Camurus AB (CAMX) Share Price Today?
The live Camurus AB share price today is 688.50
What Stock Exchange Does Camurus AB (CAMX) Trade On?
Camurus AB is listed and trades on the Stockholm Stock Exchange.
What Is the Ticker (Stock Symbol) for Camurus AB?
The stock symbol (also called a 'ticker') for Camurus AB is "CAMX."
What Is the Current Camurus AB Market Cap?
As of today, Camurus AB market capitalisation is 41.06B.
What Is Camurus AB's (CAMX) Earnings Per Share (TTM)?
The Camurus AB EPS is currently 13.04 (Trailing Twelve Months).
When Is the Next Camurus AB Earnings Date?
Camurus AB's next earnings report will be released on 12 Feb 2026.
Is CAMX a Buy or Sell From a Technical Analyst Perspective?
Based on today's Camurus AB moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Camurus AB Stock Split?
Camurus AB has split 1 times. (See the CAMX stock split history page for full effective split date and price information.)
How Many Employees Does Camurus AB Have?
Camurus AB has 280 employees.
What is the current trading status of Camurus AB (CAMX)?
As of 24 Jan 2026, Camurus AB (CAMX) is trading at a price of 688.50, with a previous close of 689.50. The stock has fluctuated within a day range of 685.00 to 696.00, while its 52-week range spans from 483.80 to 754.50.
What Is Camurus AB (CAMX) Price Target According to Analysts?
The average 12-month price target for Camurus AB is SEK808.83, with a high estimate of SEK980 and a low estimate of SEK660. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +17.48% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.